NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
NCT02076009: Phase 3 - Daratumumab, Lenalidomide & Dex (DRd) VS Len & Dexa (Rd) - MMY3003 (POLLUX)
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma
NCT02199665: Phase 1: Selinexor, Carfilzomib, & Dexamethasone in Treating Patients With RRMM (SINE)
NCT02045017: Phase 2: Efficacy & Safety of Pom and Dex in RRMM Patients With Renal Insufficiency
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY
NCT02136134: Phase 3 - Daratumumab Plus Bortezomib & Dexa in relapsed Myeloma MMY3004 (CASTOR) Study
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in Hi R SMM
NCT02315716: Phase 2 -Carfilzomib/Cyclophosphamide/Dex With Maint. Carfilzomib - NDMM Cardamon Study
NCT02322320: Phase 3 - Continued, Long-Term Follow-Up and Lenalidomide Maint. (BMT CTN 07LT)
NCT02203643: Phase 2 - Carf/Cyclo./Dex Vs Carf/Len/Dex -> ASCT or 12 Cy Carf/Len/Dex - NDMM - FORTE
NCT01863550: Phase 3 - Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in NDMM
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory MM
NCT01816971: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone Before and After ASCT NDMM
NCT01980589: Phase 1b: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in NDMM CHAMPION 2
NCT01782963: Phase 2 - Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite)
NCT01857115: Phase 1/2: EMN - Study of Wkly Carfilzomib, Cyclophosphamide and Dexamethasone In NDMM
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in NDMM or L C Amyloid